Eflornithine in Treating Patients With Bladder Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

February 28, 1999

Study Completion Date

May 31, 2007

Conditions
Bladder Cancer
Interventions
DRUG

eflornithine

Trial Locations (61)

10029

Mount Sinai Medical Center, NY, New York

11706

Medical & Clinical Research Associates, LLC, Bay Shore

12208

Cancer Center of Albany Medical Center, Albany

Veterans Affairs Medical Center - Albany, Albany

14642

University of Rochester Cancer Center, Rochester

19119

Allegheny University of the Health Sciences, Philadelphia

19141

Albert Einstein Cancer Center, Philadelphia

20037

George Washington University Hospital, Washington D.C.

20770

206 Research Associates, Greenbelt

20850

Mid Atlantic Clinical Research, Rockville

23230

Virginia Urology Center, Richmond

23507

Sentara Norfolk General Hospital, Norfolk

30060

Urology Associates, Inc., Marietta

30309

Piedmont Urology PC, Atlanta

30342

Georgia Urology, Atlanta

33761

Tampa Bay Meical Research, Clearwater

34239

Barzell, Whitmore, Treiman and Dunne - The Urology Treatment Center, Sarasota

34652

Urology Health Center, New Port Richey

35205

Urology Associates, Birmingham

35801

Intouch Research, Huntsville

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

63110

Washington University Barnard Cancer Center, St Louis

65804

Urology Surgical Associates, Springfield

67208

Wichita Clinic, P.A., Wichita

73190

University of Oklahoma College of Medicine, Oklahoma City

75231

Urology Clinics of North Texas, Dallas

76107

University of North Texas HSC, Fort Worth

78229

Urology San Antonio Research, San Antonio

84112

Huntsman Cancer Institute, Salt Lake City

87106

University Hospital of New Mexico, Albuquerque

87114

St. Joseph West Mesa Center, Albuquerque

89109

Office of Sheldon Freedman, Las Vegas

90024

Foothill Urology Associates, Pasadena

91942

San Diego Urology Center, La Mesa

92103

DRC and Urological Physicians of San Diego, San Diego

92404

San Bernadino Urological Associates, San Bernadino

92653

South Coast Urological Medical Group, Laguna Hills

92801

Advanced Urology Medical Center, Anaheim

98133

Urology Northwest PS, Seattle

91741-4164

Citrus Valley Urological Medical Group, Glendora

92093-0658

University of California San Diego Cancer Center, La Jolla

94143-0128

UCSF Cancer Center and Cancer Research Institute, San Francisco

06708

Urology Specialists, P.C., Waterbury

32610-0277

University of Florida - Gainesville, Gainesville

33612-9497

H. Lee Moffitt Cancer Center and Research Institute, Tampa

60637-1470

University of Chicago Cancer Research Center, Chicago

46202-5289

Indiana University Cancer Center, Indianapolis

66160-7353

University of Kansas Medical Center, Kansas City

01805

Lahey Clinic - Burlington, Burlington

01605

Fallon Clinic, Inc., Worcester

08903

Robert Wood Johnson Medical School, New Brunswick

43210-1240

Arthur G. James Cancer Hospital - Ohio State University, Columbus

97201-3098

Oregon Cancer Center, Portland

97213-2967

Earle A. Chiles Research Institute at Providence Portland Medical Center, Portland

19107-5541

Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia

37232-6838

Vanderbilt-Ingram Cancer Center, Nashville

75235-9154

Simmons Cancer Center - Dallas, Dallas

98104-1360

Seattle Urological Associates, Seattle

98195-6043

University of Washington Medical Center, Seattle

98431-5000

Madigan Army Medical Center, Tacoma

53792-6164

University of Wisconsin Comprehensive Cancer Center, Madison

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00003814 - Eflornithine in Treating Patients With Bladder Cancer | Biotech Hunter | Biotech Hunter